Loading...
Indian Pharmaceutical Exporter · Antimalarial & Antiparasitic Specialist · $86.4K Total Trade · DGFT Verified
Ambadnya Life Science LLP is an Indian pharmaceutical exporter with a total trade value of $86.4K across 2 products in 2 therapeutic categories. Based on 7 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Levamisole ($58.8K), Ibuprofen Paracetamol ($27.7K), .
Ambadnya Life Science LLP is an Indian pharmaceutical exporter specializing in the development and manufacturing of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Established on December 15, 2016, in Boisar, Maharashtra, the company operates under the Corporate Identification Number (CIN) AAI-0150. The registered office is located at Plot No C-9/1, MIDC Tarapur, Boisar, Maharashtra, India, 401506. The company is led by Designated Partners Nutan Rajesh Tiwari and Rajesh Ramavtar Tiwari, with Hansaraj Kamlaprasad Gupta serving as a director. Ambadnya Life Science LLP is committed to delivering quality pharmaceutical products worldwide, adhering to the WHO-GMP standards.
Ambadnya Life Science LLP operates across 2 therapeutic categories, with Antimalarial & Antiparasitic (68.0%), Combination Drugs (32.0%), representing the largest segments by export value. The portfolio is concentrated — the top 5 products account for 100% of total exports.
Antimalarial & Antiparasitic
1 products · 68.0% · $58.8K
Combination Drugs
1 products · 32.0% · $27.7K
Ambadnya Life Science LLP exports 2 pharmaceutical products across 2 therapeutic categories.
| # | Product | Category | Export Value | Shipments | Market Share | Rank |
|---|---|---|---|---|---|---|
| 1 | Levamisole | Antimalarial & Antiparasitic | $58.8K | 4 | 2.2% | 9 |
| 2 | Ibuprofen Paracetamol |
Headquarters, ownership, manufacturing facilities, and key leadership
Ambadnya Life Science LLP is an Indian pharmaceutical exporter specializing in the development and manufacturing of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Established on December 15, 2016, in Boisar, Maharashtra, the company operates under the Corporate Identification Number (CIN) AAI-0150. The registered office is located at Plot No C-9/1, MIDC Tarapur, Boisar, Maharashtra, India, 401506. The company is led by Designated Partners Nutan Rajesh Tiwari and Rajesh Ramavtar Tiwari, with Hansaraj Kamlaprasad Gupta serving as a director. Ambadnya Life Science LLP is committed to delivering quality pharmaceutical products worldwide, adhering to the WHO-GMP standards.
The company's manufacturing facility is situated in Boisar, Maharashtra, within the MIDC Tarapur industrial area. This location is strategically chosen to leverage the region's industrial infrastructure and proximity to key markets. The facility is equipped with fully automated equipment and ultra-modern facilities, ensuring compliance with Current Good Manufacturing Practices (CGMP). While specific production capacities and specializations are not publicly disclosed, the company's focus on quality and adherence to international standards underscore its commitment to excellence in pharmaceutical manufacturing.
| $27.7K |
| 3 |
1.4% |
| 6 |
Ambadnya Life Science LLP exports 2 pharmaceutical products across 2 therapeutic categories with a total export value of $86.4K. The top category is Antimalarial & Antiparasitic (68.0% of portfolio), followed by Combination Drugs (32.0%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.
Shipment-level records, pricing & buyer contacts for Ambadnya Life Science LLP.
Request DemoAmbadnya Life Science LLP is guided by a team of experienced leaders:
These leaders bring a wealth of experience to the company, steering its strategic direction and operational excellence.
Regulated market presence, emerging market penetration, and geographic strategy
Ambadnya Life Science LLP's export portfolio, valued at $86,000 USD over seven shipments, includes two products across two therapeutic categories. The top products are Levamisole ($59,000 USD) and Ibuprofen Paracetamol ($28,000 USD), with market shares of 2.2% and 1.4%, respectively. The primary therapeutic categories are Antimalarial & Antiparasitic (68.0%) and Combination Drugs (32.0%). The company's focus on these categories suggests a strategic alignment with global health priorities, particularly in regions where these treatments are in demand. However, specific details regarding regulatory filings, approvals, and market access status in the US, EU, UK, Australia, and Japan are not publicly available. This lack of publicly disclosed information may indicate that the company is in the early stages of entering these markets or has not yet pursued regulatory approvals in these regions.
Ambadnya Life Science LLP has demonstrated a presence in emerging markets, notably in Africa and Latin America. The company's export data indicates shipments to countries such as the Democratic Republic of the Congo and the Republic of the Congo. While specific details about WHO prequalification are not available, the company's adherence to WHO-GMP standards suggests a commitment to meeting international quality benchmarks, which is essential for accessing and expanding in these emerging markets.
Ambadnya Life Science LLP's export activities reflect a strategic focus on regions with significant demand for Antimalarial & Antiparasitic and Combination Drugs. The concentration of 100% of its export value in the top five products indicates a focused product strategy. However, the limited number of shipments (seven) suggests that the company may be in the early stages of its export operations, potentially mitigating concentration risk. The strategic direction appears to be centered on establishing a foothold in select international markets, with a focus on quality and compliance with international standards.
FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record
Specific information regarding Ambadnya Life Science LLP's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history is not publicly available. This lack of publicly disclosed information may indicate that the company has not pursued FDA approvals or registrations for its products. For importers and partners, it is advisable to verify the company's compliance with FDA regulations and approvals before engaging in business transactions.
Ambadnya Life Science LLP's commitment to quality is evidenced by its adherence to WHO-GMP standards. The company's manufacturing facility is equipped with fully automated equipment and ultra-modern facilities, ensuring compliance with Current Good Manufacturing Practices (CGMP). However, specific certifications such as WHO prequalification, EU GMP certificates, and EDQM status are not publicly disclosed. Importers and partners should verify the company's certifications and compliance with international quality standards before proceeding with business engagements.
Ambadnya Life Science LLP operates under the regulatory framework of the Central Drugs Standard Control Organisation (CDSCO) in India. The company's manufacturing facility is located in Boisar, Maharashtra, within the MIDC Tarapur industrial area. Specific details regarding CDSCO manufacturing licenses, state drug controller approvals, and export No Objection Certificates (NOCs) are not publicly available. Importers and partners should verify the company's compliance with Indian regulatory requirements before engaging in business transactions.
As of March 28, 2026, there are no publicly available records indicating any Form 483 observations, warning letters, or import alerts associated with Ambadnya Life Science LLP. This absence of publicly disclosed regulatory actions suggests that the company maintains a compliant operational status. However, it is advisable for importers and partners to conduct thorough due diligence to ensure ongoing compliance with relevant regulatory standards.
Market share comparison, key differentiators, and strategic analysis
Ambadnya Life Science LLP operates in the competitive pharmaceutical export market, focusing on Antimalarial & Antiparasitic and Combination Drugs. While specific competitors in these therapeutic categories are not identified, the company's export data indicates a presence in markets such as the Democratic Republic of the Congo and the Republic of the Congo. The company's focus on quality, adherence to WHO-GMP standards, and strategic product portfolio may provide a competitive edge in these regions. However, the limited number of shipments and market share suggest that the company is in the early stages of establishing its presence in these markets.
Ambadnya Life Science LLP's key differentiators include its commitment to quality, adherence to WHO-GMP standards, and focus on specific therapeutic categories such as Antimalarial & Antiparasitic and Combination Drugs. The company's manufacturing facility is equipped with fully automated equipment and ultra-modern facilities, ensuring compliance with Current Good Manufacturing Practices (CGMP). These factors contribute to the company's ability to deliver high-quality pharmaceutical products to international markets.
Ambadnya Life Science LLP's current strategic direction appears to be focused on establishing a foothold in select international markets, particularly in regions with significant demand for Antimalarial & Antiparasitic and Combination Drugs. The company's adherence to WHO-GMP standards and commitment to quality underscore its strategic emphasis on compliance and product excellence. The limited number of shipments and market share suggest that the company is in the early stages of its export operations, with potential for growth as it expands its market presence.
Track record assessment, certifications to verify, and pre-order checks
Ambadnya Life Science LLP has demonstrated a presence in international markets, with export data indicating shipments to countries such as the Democratic Republic of the Congo and the Republic of the Congo. The company's focus on quality, adherence to WHO-GMP standards, and strategic product portfolio suggest a commitment to reliability and consistency. However, the limited number of shipments and market share indicate that the company is in the early stages of its export operations. Importers and partners should conduct thorough due diligence to assess the company's track record, export volume, and consistency before engaging in business transactions.
Importers should verify the following certifications before engaging with Ambadnya Life Science LLP:
Ambadnya Life Science LLP exports 2 pharmaceutical products across 2 therapeutic categories. The top exports are Levamisole ($58.8K), Ibuprofen Paracetamol ($27.7K). Total export value is $86.4K.
Ambadnya Life Science LLP's total pharmaceutical export value is $86.4K, based on 7 verified shipments recorded in Indian Customs (DGFT) data.
Ambadnya Life Science LLP exports across 2 therapeutic categories. The largest are Antimalarial & Antiparasitic (68.0%, 1 products), Combination Drugs (32.0%, 1 products).
Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Verify manufacturer licensing, GMP certification, and export registration with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
2 Products Tracked
2 therapeutic categories
Expert-Reviewed
By pharmaceutical trade specialists
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.